While business is historically slow in August, this month seems to be bucking the trend, just like so many other unexpected developments in 2020. Perhaps life sciences executives have been less distracted by summer excursions this year in a world in which the COVID-19 pandemic has significantly curtailed travel.
This week two pharmaceutical companies announced major acquisition agreements collectively valued at more than $10 billion, and a trio of biotechs—one with preclinical programs, another with Phase 1 trials underway, and a third with its first drug commercialized less than a year ago—raised a combined $421 million from public investors. It was a... Read more »
Author: Sarah de Crescenzo
Date : 2020-08-21T13:39:29.000Z